Using Aphidicolin to Overcome Drug Resistance in AML
Author Information
Author(s): Sargent J M, Elgie A W, Williamson C J, Lewandowicz G M, Taylor C G
Primary Institution: Haematology Research, Pembury Hospital, Pembury, Kent, TN2 4QJ, UK
Hypothesis
Can the DNA repair inhibitor aphidicolin enhance the sensitivity of AML blast cells to ara-C?
Conclusion
Aphidicolin significantly increases the sensitivity of resistant AML cells to ara-C without increasing toxicity to normal cells.
Supporting Evidence
- Aphidicolin increased sensitivity to ara-C by a median of 4.75-fold.
- The effect was greater in cells resistant to ara-C, with an 8.9-fold increase.
- The combination of ara-C and aphidicolin showed no increased myelotoxicity compared to ara-C alone.
Takeaway
Researchers found that a drug called aphidicolin can help make a cancer treatment more effective for some patients without hurting healthy cells.
Methodology
Blast cells from AML patients were exposed to various agents with and without aphidicolin, and cell survival was measured using the MTT assay.
Participant Demographics
22 patients with AML and 10 cord blood samples.
Statistical Information
P-Value
p<0.005
Confidence Interval
0.8–80-fold
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website